Evidence map›Paper›PMID 30417001›Full record

ReviewFrontiers in cardiovascular medicine2018

Algal Polysaccharides as Therapeutic Agents for Atherosclerosis.

Nikita P Patil, Victoria Le, Andrew D Sligar, Lei Mei, Daniel Chavarria, Emily Y Yang, Aaron B Baker

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in cardiovascular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
14.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 127 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Cardiovascular therapeutics · 2024
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Biological properties and potential of compounds extracted from red seaweeds.Phytochemistry reviews : proceedings of the Phytochemical Society of Europe · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Nikita P PatilDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, United States.
Victoria LeDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, United States.
Andrew D SligarDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, United States.
Lei MeiDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, United States.
Daniel ChavarriaDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, United States.
Emily Y YangDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, United States.
Aaron B BakerDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, United States.
The University of Texas at Austin · US

Funding

Comprehensive Training Program in Imaging Science and InformaticsT32EB007507 · NIBIB · UNIVERSITY OF TEXAS AT AUSTIN · PI MARKEY, MIA K, RYLANDER, HENRY GRADY · 2009 to 2024
$2.7M
Mechanical Conditioning of Mesenchymal Stem Cells for Enhanced Recellularized Vascular GraftsR01HL141761 · NHLBI · UNIVERSITY OF TEXAS AT AUSTIN · PI BAKER, AARON BLAIR · 2018 to 2021
$1.6M
Syndecan-1 in Mechanosensing of Engineered MicroenvironmentsR21EB023551 · NIBIB · UNIVERSITY OF TEXAS AT AUSTIN · PI BAKER, AARON BLAIR · 2017 to 2018
$450k
Glycocalyx Mimetic Polysaccharides as Therapeutics for AtherosclerosisR21EB024147 · NIBIB · UNIVERSITY OF TEXAS AT AUSTIN · PI BAKER, AARON BLAIR · 2017 to 2018
$430k
NHLBI NIH HHS R01 HL141761NIBIB NIH HHS R21 EB023551NIBIB NIH HHS R21 EB024147NIBIB NIH HHS T32 EB007507
6 · The paper itself

Abstract

Seaweed-derived polysaccharides including agar and alginate, have found widespread applications in biomedical research and medical therapeutic applications including wound healing, drug delivery, and tissue engineering. Given the recent increases in the incidence of diabetes, obesity and hyperlipidemia, there is a pressing need for low cost therapeutics that can economically and effectively slow the progression of atherosclerosis. Marine polysaccharides have been consumed by humans for millennia and are available in large quantities at low cost. Polysaccharides such as fucoidan, laminarin sulfate and ulvan have shown promise in reducing atherosclerosis and its accompanying risk factors in animal models. However, others have been tested in very limited context in scientific studies. In this review, we explore the current state of knowledge for these promising therapeutics and discuss the potential and challenges of using seaweed derived polysaccharides as therapies for atherosclerosis.

Indexed as

alginateatherosclerosisfucoidanhyperlipidemialaminarinmicrobiomeseaweedulvan

Identifiers

PMID30417001
PMCPMC6214344
OpenAlexW2898292656

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.